Exonic polymorphism (rs315952, Ser133Ser) of interleukin 1 receptor antagonist (IL1RN) is related to overweigh/obese with hypertension

Yang, Seung-Ae

doi:10.12965/jer.140155

Cited by 6 publications

(24 citation statements)

References 22 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies suggested that IL-1 receptor antagonist plays a great role in metabolic effects and that one synonymous SNP (rs315952, Ser133Ser) of the IL1RN gene was associated with development of obesity and hypertension [67]. Therefore, a therapeutic option targeting several comorbidities may be reducing the activity or expression of Il-1 β or IL-1 receptor 1 [58, 68].…”

Section: Inflammation In Arterial Hypertensionmentioning

confidence: 99%

Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?

Tanase

Gosav

Radu³

et al. 2019

International Journal of Hypertension

View full text Add to dashboard Buy / Rent full text

Hypertension as a multifactorial pathology is one of the most important cardiovascular risk factors, affecting up to 30-40% of the general population. Complex immune responses are involved in the inflammatory mechanism of hypertension, with evidence pointing to increased inflammatory mediators even in prehypertensive patients. Increased vascular permeability, thrombogenesis, and fibrosis, effects that are associated with sustained hypertension, could be attributed to chronic inflammation. Chronic inflammation triggers endothelial dysfunction via increased production of ROS through proinflammatory cytokines. Increased serum level of proinflammatory cytokines such as IL-1β, IL-6, IL-8, IL-17, IL-23, TGFβ, and TNFα in hypertensive patients has been associated with either increased blood pressure values and/or end-organ damage. Moreover, some cytokines (i.e., IL-6) seem to determine a hypertensive response to angiotensin II, regardless of blood pressure values. Understanding hypertension as an inflammatory-based pathology gives way to new therapeutic targets. As such, conventional cardiovascular drugs (statins, calcium channels blockers, and ACEIs/ARBs) have shown additional anti-inflammatory effects that could be linked to their blood pressure lowering properties. Moreover, anti-inflammatory drugs (mycophenolate mofetil) have been shown to decrease blood pressure in hypertensive patients or prevent its development in normotensive individuals. Further research is needed to evaluate whether drugs targeting hypertensive-linked proinflammatory cytokines, such as monoclonal antibodies, could become a new therapeutic option in treating arterial hypertension.

show abstract

Section: Inflammation In Arterial Hypertensionmentioning

confidence: 99%

Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?

Tanase

Gosav

Radu³

et al. 2019

International Journal of Hypertension

View full text Add to dashboard Buy / Rent full text

show abstract

“…Use of these ACE inhibitors in hypertensive rats led to significantly decreased LPS-stimulated TNF-α and IL-1β levels, highlighting the ability of these drugs to attenuate inflammation [ 200 ]. Different studies revealed that polymorphisms in the IL-1β gene are associated with higher blood pressure in ethnic populations [ 165 , 201 , 202 ]; however, the question still remains whether IL-1β and IL-18 are inflammatory markers or mediators of hypertension in humans [ 203 ]. Serum levels of IL-1β and IL-1RA were described as predictors of elevated diastolic blood pressure in 537 subjects with insulin resistance syndrome [ 204 ].…”

Section: Targeting the Nlrp3 Inflammasome And Pyroptosis In Hypertmentioning

confidence: 99%

Emerging Role of the Inflammasome and Pyroptosis in Hypertension

Miguel

Pelegrín

Baroja-Mazo

et al. 2021

IJMS

View full text Add to dashboard Buy / Rent full text

Inflammasomes are components of the innate immune response that have recently emerged as crucial controllers of tissue homeostasis. In particular, the nucleotide-binding domain, leucine-rich-containing (NLR) family pyrin domain containing 3 (NLRP3) inflammasome is a complex platform involved in the activation of caspase-1 and the maturation of interleukin (IL)-1β and IL-18, which are mainly released via pyroptosis. Pyroptosis is a caspase-1-dependent type of cell death that is mediated by the cleavage of gasdermin D and the subsequent formation of structurally stable pores in the cell membrane. Through these pores formed by gasdermin proteins cytosolic contents are released into the extracellular space and act as damage-associated molecular patterns, which are pro-inflammatory signals. Inflammation is a main contributor to the development of hypertension and it also is known to stimulate fibrosis and end-organ damage. Patients with essential hypertension and animal models of hypertension exhibit elevated levels of circulating IL-1β. Downregulation of the expression of key components of the NLRP3 inflammasome delays the development of hypertension and pharmacological inhibition of this inflammasome leads to reduced blood pressure in animal models and humans. Although the relationship between pyroptosis and hypertension is not well established yet, pyroptosis has been associated with renal and cardiovascular diseases, instances where high blood pressure is a critical risk factor. In this review, we summarize the recent literature addressing the role of pyroptosis and the inflammasome in the development of hypertension and discuss the potential use of approaches targeting this pathway as future anti-hypertensive strategies.

show abstract

“…(17)(18)(19)(20)(21)(22)(23)(24)(25)(26). However, the association of these polymorphisms with several diseases in different populations is controversial (Table 2).…”

Section: Functional Predictionmentioning

confidence: 99%

The interleukin-1β-511 T>C (rs16944) gene polymorphism is associated with risk of developing silent myocardial ischemia in diabetic patients

Vargas-Alarcón¹,

Cruz-López

Valladares

et al. 2015

Immunology Letters

View full text Add to dashboard Buy / Rent full text

Exonic polymorphism (rs315952, Ser133Ser) of interleukin 1 receptor antagonist (IL1RN) is related to overweigh/obese with hypertension

Cited by 6 publications

References 22 publications

Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?

Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?

Emerging Role of the Inflammasome and Pyroptosis in Hypertension

The interleukin-1β-511 T>C (rs16944) gene polymorphism is associated with risk of developing silent myocardial ischemia in diabetic patients

Contact Info

Product

Resources

About